Inagaki M, Michimata H, Minato K, Sunaga Y, Kobayashi S, Tani G, Nakazawa T
First Department of Internal Medicine, Gunma University School of Medicine.
Nihon Kyobu Shikkan Gakkai Zasshi. 1992 Jun;30(6):1180-5.
The anti-allergic action of amlexanox is reported to be associated with inhibition of the release of LTC4, LTD4 and histamine, and with antagonistic activity on leukotrienes. The patient was a 18-year-old female who had suffered from bronchial asthma since the age of fifteen. We diagnosed the case as aspirin sensitive asthma because of development of a severe asthmatic attack with syncope after oral administration of an analgesic for treatment of a common cold at the age of seventeen. She also had sensitivity to toothpaste. Three-minute aerosol inhalation challenge with 0.1, 1 and 10% solution of sulpyrine was performed as a stepwise increment at 20 minutes intervals. This inhalation test was positive and it evoked simultaneous increases of LTC4, LTD4 and histamine in the peripheral blood. Since the commencement of oral administration of 150 mg per day of amlexanox, the patient has had no attacks for about 8 months. In the second inhalation test, premedication with amlexanox elevated the threshold of sulpyrine and inhibited the release of LTC4, LTD4 and histamine. We report that amlexanox was of use to control asthmatic attacks in this aspirin-sensitive asthmatic patient.
据报道，氨来呫诺的抗过敏作用与抑制白三烯C4、白三烯D4和组胺的释放以及对白三烯的拮抗活性有关。该患者为一名18岁女性，自15岁起就患有支气管哮喘。17岁时，她因口服一种用于治疗普通感冒的镇痛药后出现严重哮喘发作并伴有晕厥，我们将该病例诊断为阿司匹林敏感性哮喘。她还对牙膏敏感。以20分钟的间隔逐步递增，用0.1%、1%和10%的舒必利溶液进行三分钟气雾剂吸入激发试验。该吸入试验呈阳性，它引起外周血中白三烯C4、白三烯D4和组胺同时增加。自开始每天口服150毫克氨来呫诺以来，该患者约8个月未发作。在第二次吸入试验中，氨来呫诺预处理提高了舒必利的阈值，并抑制了白三烯C4、白三烯D4和组胺的释放。我们报道氨来呫诺对控制该阿司匹林敏感性哮喘患者的哮喘发作有用。
